These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32425303)

  • 1. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
    Dabaghian F; Khanavi M; Zarshenas MM
    Med Hypotheses; 2020 Oct; 143():109841. PubMed ID: 32425303
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 3. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
    [No Abstract]   [Full Text] [Related]  

  • 4. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

  • 5. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.
    Sparks MA; South A; Welling P; Luther JM; Cohen J; Byrd JB; Burrell LM; Batlle D; Tomlinson L; Bhalla V; Rheault MN; Soler MJ; Swaminathan S; Hiremath S
    Clin J Am Soc Nephrol; 2020 May; 15(5):714-716. PubMed ID: 32220930
    [No Abstract]   [Full Text] [Related]  

  • 6. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
    Malek Mahdavi A
    Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
    Roshanravan N; Ghaffari S; Hedayati M
    Diabetes Metab Syndr; 2020; 14(4):637-639. PubMed ID: 32428864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II suppression in SARS-CoV-2 infection: a therapeutic approach.
    Lamas-Barreiro JM; Alonso-Suárez M; Fernández-Martín JJ; Saavedra-Alonso JA
    Nefrologia (Engl Ed); 2020; 40(3):213-216. PubMed ID: 32456945
    [No Abstract]   [Full Text] [Related]  

  • 9. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of ACEIs/ARBs in COVID-19: Friend or foe?
    Zhou Z; Qiu Y; Tao J
    Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701
    [No Abstract]   [Full Text] [Related]  

  • 11. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
    Zemlin AE; Wiese OJ
    Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 and Cardiovascular Disease.
    Clerkin KJ; Fried JA; Raikhelkar J; Sayer G; Griffin JM; Masoumi A; Jain SS; Burkhoff D; Kumaraiah D; Rabbani L; Schwartz A; Uriel N
    Circulation; 2020 May; 141(20):1648-1655. PubMed ID: 32200663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covid-19: the renin-angiotensin system imbalance hypothesis.
    Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
    Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
    South AM; Tomlinson L; Edmonston D; Hiremath S; Sparks MA
    Nat Rev Nephrol; 2020 Jun; 16(6):305-307. PubMed ID: 32246101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
    Danser AHJ; Epstein M; Batlle D
    Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [De første kliniske data fra RASi-behandlede indlagte patienter med COVID-19 kommer nu, og vi skal ikke ændre medicinering].
    Madsen PL
    Ugeskr Laeger; 2020 May; 182(20):. PubMed ID: 32400381
    [No Abstract]   [Full Text] [Related]  

  • 17. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
    Sommerstein R; Kochen MM; Messerli FH; Gräni C
    J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
    [No Abstract]   [Full Text] [Related]  

  • 18. Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2.
    Skayem C; Ayoub N
    Am J Med Sci; 2020 Sep; 360(3):300. PubMed ID: 32631576
    [No Abstract]   [Full Text] [Related]  

  • 19. ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.
    Onweni CL; Zhang YS; Caulfield T; Hopkins CE; Fairweather L; Freeman WD
    Crit Care; 2020 Jul; 24(1):475. PubMed ID: 32736573
    [No Abstract]   [Full Text] [Related]  

  • 20. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
    Cheng H; Wang Y; Wang GQ
    J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.